Compugen Ltd has signed a research collaboration agreement with Seattle Genetics, Inc, USA, covering a Compugen-discovered oncology target. The agreement provides Seattle Genetics with an initial evaluation period and an option for an exclusive worldwide milestone and royalty bearing license for development and commercialization of monoclonal antibody therapeutics addressing this novel target.
The existence of the target, which is a previously unknown splice variant of a known oncology target, was initially predicted in silico through the use of Compugen’s Monoclonal Antibody (mAb) Targets Discovery Platform. The predicted molecule’s existence and overexpression in several of the most prevalent solid cancers was recently demonstrated in independent experimentally based studies.
Dr Anat Cohen-Dayag, president & CEO of Compugen stated, “We are very enthusiastic about this new collaboration, our first with Seattle Genetics, a leading company in the rapidly growing field of monoclonal antibodies and antibody drug conjugates. The Compugen novel target that is the subject of this agreement has shown potential in a number of important unmet areas of cancer treatment.”
Dr Cohen-Dayag continued, “We also are pleased to see the continuing and growing interest of the industry with respect to our mAb Targets Discovery Platform. This unique capability, which addresses the key unmet market need in the rapidly growing antibody therapeutic field, is now serving as both the source of targets for collaborations, such as the one being announced today and our ongoing collaboration with Bayer Schering Pharma, and also to predict and select, in combination with other Compugen tools and capabilities, an inventory of potential targets for further internal development under the new program disclosed earlier this week in our quarterly press release.”
Martin Gerstel, Compugen’s chairman added, “As described in the quarterly release, our business model provides three potential pathways for development and commercialization of our product candidate discoveries. Collaborations can be entered into before our prediction and selection of candidates is undertaken pursuant to ‘discovery on demand’ agreements, or with respect to existing Compugen product candidates, collaborations can be initiated prior to or at the proof of concept stage, or after additional preclinical activities have been undertaken by us. In all cases these agreements provide Compugen with potential milestone payments and royalties on product sales or other revenue sharing arrangements. The decision as to which pathway we choose in each specific case will depend on many factors, such as proprietary knowledge or technology of a potential partner that could expedite and increase the probability of success of development or commercialization; the anticipated overall relationship with the potential partner; our assessment of the risk/reward profile of further development by us; and available financial terms at each point in time.”
Compugen is a leading drug and diagnostic product candidate discovery company. Unlike traditional high throughput trial and error experimental based discovery, Compugen’s discovery efforts are based on in silico (by computer) product candidate prediction and selection utilizing a broad and continuously growing infrastructure of proprietary scientific understandings and predictive platforms, algorithms, machine learning systems and other computational biology tools to address important unmet therapeutic and diagnostic needs - either for Compugen or its partners.